Marinus Pharmaceuticals (NASDAQ:MRNS) Coverage Initiated at StockNews.com

Investment analysts at StockNews.com started coverage on shares of Marinus Pharmaceuticals (NASDAQ:MRNS) in a report released on Monday. The firm set a “sell” rating on the biopharmaceutical company’s stock.

Several other brokerages also recently weighed in on MRNS. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $4.00 target price on shares of Marinus Pharmaceuticals in a research note on Thursday, November 14th. HC Wainwright reiterated a “neutral” rating and issued a $2.00 price objective on shares of Marinus Pharmaceuticals in a research note on Thursday, November 14th. Royal Bank of Canada decreased their target price on Marinus Pharmaceuticals from $3.00 to $1.00 and set a “sector perform” rating for the company in a report on Friday, October 25th. Jefferies Financial Group reaffirmed a “hold” rating and issued a $0.50 price target (down previously from $5.00) on shares of Marinus Pharmaceuticals in a research report on Friday, October 25th. Finally, Truist Financial downgraded shares of Marinus Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Thursday, October 24th. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating, two have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, Marinus Pharmaceuticals presently has an average rating of “Hold” and a consensus price target of $4.79.

Marinus Pharmaceuticals Price Performance

Shares of NASDAQ:MRNS opened at $0.54 on Monday. The firm has a market capitalization of $29.76 million, a PE ratio of -0.22 and a beta of 1.03. Marinus Pharmaceuticals has a 1 year low of $0.22 and a 1 year high of $10.50. The firm’s 50-day moving average is $0.36 and its two-hundred day moving average is $1.00.

Hedge Funds Weigh In On Marinus Pharmaceuticals

Several large investors have recently bought and sold shares of MRNS. JPMorgan Chase & Co. increased its position in shares of Marinus Pharmaceuticals by 1,968.5% during the third quarter. JPMorgan Chase & Co. now owns 133,191 shares of the biopharmaceutical company’s stock worth $234,000 after purchasing an additional 126,752 shares in the last quarter. Franklin Resources Inc. lifted its stake in Marinus Pharmaceuticals by 34.9% in the third quarter. Franklin Resources Inc. now owns 4,713,014 shares of the biopharmaceutical company’s stock valued at $8,483,000 after buying an additional 1,219,871 shares during the last quarter. World Investment Advisors LLC purchased a new stake in Marinus Pharmaceuticals in the third quarter valued at approximately $104,000. Jacobs Levy Equity Management Inc. boosted its holdings in shares of Marinus Pharmaceuticals by 39.5% in the third quarter. Jacobs Levy Equity Management Inc. now owns 414,269 shares of the biopharmaceutical company’s stock valued at $729,000 after acquiring an additional 117,255 shares during the period. Finally, Suvretta Capital Management LLC grew its position in shares of Marinus Pharmaceuticals by 32.8% during the third quarter. Suvretta Capital Management LLC now owns 5,073,913 shares of the biopharmaceutical company’s stock worth $8,930,000 after acquiring an additional 1,253,901 shares during the last quarter. Institutional investors and hedge funds own 98.80% of the company’s stock.

About Marinus Pharmaceuticals

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.